North American Report

Heart Failure Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

 Breaking News
  • No posts were found

Heart Failure Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

October 20
12:26 2021
Heart Failure Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
DelveInsight Business Research LLP
DelveInsight’s, “Heart Failure – Pipeline Insight, 2021,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Heart Failure pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

DelveInsight’sHeart Failure Pipeline Insightreport provides comprehensive insights about key companies and pipeline drugs in the Heart Failure pipeline landscapes. It comprises Heart Failure pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Heart Failure therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Heart Failure pipeline products.     

Some of the key takeaways of the Heart Failure Pipeline Report  

  • Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players Boehringer Ingelheim/Eli Lilly and Company, Merck Sharp & Dohme Corp/Bayer, AstraZeneca, such as, etc., are developing therapies for the treatment of Heart Failure.

  • Emerging therapies such as Empagliflozin, Vericiguat, AZD4831 & Dapagliflozin, Omecamtiv mecarbil, are expected to have a significant impact on the  Heart Failure market in the coming years.

Get an overview of pipeline landscape @ Heart Failure Clinical Trials Analysis 

Heart Failure Overview

Heart Failure (HF) is also known as congestive HF. It is also bifurcated as left-side HF (when the heart is unable to pump enough oxygen in the blood to the body) and right-side HF (when the heart is unable to fill itself with enough blood). Another term for HF is corpulmonale which means that right-side HF is caused by high blood pressure in the pulmonary arteries and right ventricle.

Heart Failure Emerging Drugs

  • Empagliflozin: Boehringer Ingelheim/Eli Lilly and Company

  • Vericiguat: Merck Sharp & Dohme Corp/Bayer

  • AZD4831 & Dapagliflozin: AstraZeneca

  • Omecamtiv mecarbil: Amgen, and others

For further information, refer to the detailed report @ Heart Failure Pipeline Therapeutics 

Scope of Heart Failure Pipeline Drug Insight    

  • Coverage: Global 

  • Major Players: Boehringer Ingelheim/Eli Lilly and Company, Merck Sharp & Dohme Corp/Bayer, AstraZeneca, and others.

  • Pipeline Therapies: Empagliflozin, Vericiguat, AZD4831 & Dapagliflozin, Omecamtiv mecarbil, and others.

Table of Contents

1

Heart Failure Report Introduction

2

Heart Failure Executive Summary

3

Heart Failure Overview

4

Heart Failure- Analytical Perspective In-depth Commercial Assessment

5

Heart Failure Pipeline Therapeutics

6

Heart Failure Late Stage Products (Phase II/III)

7

Heart Failure Mid Stage Products (Phase II)

8

Heart Failure Early Stage Products (Phase I)

9

Heart Failure Preclinical Stage Products

10

Heart Failure Therapeutics Assessment

11

Heart Failure Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Heart Failure Key Companies

14

Heart Failure Key Products

15

Heart Failure Unmet Needs

16 

Heart Failure Market Drivers and Barriers

17

Heart Failure Future Perspectives and Conclusion

18

Heart Failure Analyst Views

19

Appendix

20

About DelveInsight

Get a customized pipeline report @ Heart Failure Drugs Pipeline Report. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/